Retinal Vein Occlusion Emerging and Marketed Drugs Assessment (2023 Updates) | Clinical Trials Evaluation, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, Competitive Landscape, Key Companies

March 29 06:08 2023
Retinal Vein Occlusion Emerging and Marketed Drugs Assessment (2023 Updates) | Clinical Trials Evaluation, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, Competitive Landscape, Key Companies
Delveinsight Business Research LLP
As per DelveInsight’s assessment, about 15+ key pharma and biotech companies are working on 15+ pipeline drugs in the Retinal Vein Occlusion therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

As per DelveInsight, the Retinal Vein Occlusion therapeutics market is anticipated to evolve immensely in the coming years owing to the expected launch of potential therapies and an increase in the diagnosed prevalent population of Retinal Vein Occlusion.

Retinal Vein Occlusion Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Retinal Vein Occlusion Market. 

The Retinal Vein Occlusion Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from pre-clinical developmental to marketed phases. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

At present, there is no treatment available to reverse Retinal Vein Occlusion. Most people with this condition will permanently change their vision, and the main goal of the available treatment is to stabilize vision by sealing off leaking blood vessels. However, several major pharma and biotech giants such as AbbVie, Roche, Regeneron Pharmaceuticals, Taiwan Liposome Company, Aerie Pharmaceuticals, Graybug Vision, Outlook Therapeutics, Kodiak Sciences Inc, Chugai Pharmaceuticals, and others are actively working in the therapeutic market.


The pipeline for RVO is dynamic, consisting of TLC399 (ProDex), AR1105, GB102, ONS-5010/Lytenava, Vabysmo, and KSI-301 in the late stages of development. Besides these, other therapies in the early stages include MHU650, ANXV, Autologous Bone Marrow CD34+ Stem Cells, and AXT107, among others.

Retinal Vein Occlusion Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for the treatment of Retinal Vein Occlusion and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Retinal Vein Occlusion market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Route of Administration

Retinal Vein Occlusion pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

  • Oral

  • Parenteral

  • Intravitreal

  • Subretinal

  • Topical

Molecule Type

Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy

Learn How the Ongoing Clinical & Commercial Activities will Affect the Retinal Vein Occlusion Therapeutic Segment @

Retinal Vein Occlusion Therapeutics Landscape

Several major pharma and biotech companies are developing therapies for Retinal Vein Occlusion. Currently, Kodiak sciences are leading the therapeutics market with its Retinal Vein Occlusion drug candidates in the mid to advanced stage of clinical development.

The Leading Companies in the Retinal Vein Occlusion Therapeutics Market Include:

  • AbbVie

  • Aerie Pharmaceuticals

  • Allergan

  • Chugai Pharmaceuticals

  • Genentech

  • Graybug Vision

  • Kodiak Sciences

  • Kodiak Sciences Inc

  • Novartis Pharmaceuticals

  • Outlook Therapeutics

  • Regeneron Pharmaceuticals

  • Ripple Therapeutics

  • Roche

  • Sunshine Guojian Pharmaceutical

  • Taiwan Liposome Company

  • The Emmes Company

And Many Others

 Retinal Vein Occlusion Emerging and Marketed Drugs Covered in the Report Include:

  • 601: Sunshine Guojian Pharmaceutical

  • AR-1105: Aerie Pharmaceuticals

  • Eylea (aflibercept): Regeneron Pharmaceuticals

  • GB-102 (sunitinib/sunitinib malate): Graybug Vision

  • IBE-814: Ripple Therapeutics

  • KSI-301: Kodiak Sciences),

  • Lucentis intravitreal injection (ranibizumab): Genentech

  • ONS-5010/Lytenava(bevacizumab-vikg): Outlook Therapeutics

  • Ozurdex (dexamethasone): AbbVie

  • TLC399/ProDex: Taiwan Liposome Company

  • Vabysmo (faricimab/RG7716): Roche/ Chugai Pharmaceutical

And Many More 

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Retinal Vein Occlusion Current Treatment Patterns

4. Retinal Vein Occlusion – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Retinal Vein Occlusion Late Stage Products (Phase-III)

7. Retinal Vein Occlusion Mid-Stage Products (Phase-II)

8. Retinal Vein Occlusion Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Retinal Vein Occlusion Discontinued Products

13. Retinal Vein Occlusion Product Profiles

14. Key Companies in the Retinal Vein Occlusion Market

15. Key Products in the Retinal Vein Occlusion Therapeutics Segment

16. Dormant and Discontinued Products

17. Retinal Vein Occlusion Unmet Needs

18. Retinal Vein Occlusion Future Perspectives

19. Retinal Vein Occlusion Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:


Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving pharmaceutical market today @ Pharmaceutical Partner Identification Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States

view more articles

About Article Author